Haemorrhage due to proteolysis of FXIII and hyperfibrinolysis under vemurafenib treatment of metastatic melanoma

摘要

Vemurafenib, an orally available inhibitor of mutated BRAF (v-Raf sarcoma viral on-cogene homolog Bl), has been reported to improve overall survival in metastatic melanoma with major side effects including arthralgia, rash, fatigue, alopecia, keratoac-anthoma, squamous-cell carcinoma, photosensitivity, nausea, and diarrhoea (1). We present an unusual case of severe haemorrhage after initiation of vemurafenib treatment.